(Reuters) – Euroapi shares collapsed to their lowest price ever recorded on Tuesday on the stock market, after the French pharmaceutical company reduced its forecasts for 2023 and suspended its medium-term targets.
The company now expects net revenue growth of between +3% and +5%, compared to +7% to +8% previously, and a core Ebitda margin of between 9% and 11%, compared to 12.5%. at 13.5% previously.
The stock hit a low of 4.7 euros and today’s losses wiped out 643.3 million euros of market capitalization. At 08:07 GMT, the stock was down 58.54%, heading for its worst fall in a session.
Euroapi explained the slowdown in turnover in 2023 by the evolution of the market environment, with pressure on prices for its API solutions and delayed projects for its CMDO activities.
JPMorgan says the new guidance implies a 3% reduction in expected revenue for 2023 and a 25% reduction in expected Ebitda.
Euroapi said it was launching a strategic review aimed at adapting its operating model and suspending its 2023-2026 medium-term outlook communicated earlier this year.
“Given the uncertainty over the mid-term outlook and revenue and margins, we expect the stock to decline at least in line with the expected consensus earnings reductions for 2023 and 2024, and therefore the stock will fall by 30 to 35%,” adds JPMorgan.
(Written by Clement Martinot, Corentin Chappron, edited by Kate Entringer)
Copyright © 2023 Thomson Reuters
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
